Identification of a Genetic Signature Enriching for Response to Ibrutinib in Relapsed/Refractory Follicular Lymphoma in the Dawn Phase 2 Trial
Year: 2018
Type: conference-abstract
Source: Blood
Institutions: Abramson Cancer Center, University of Pennsylvania, The University of Texas MD Anderson Cancer Center, The University of Sydney, Concord Repatriation General Hospital, Johannes Gutenberg University Mainz, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Janssen Research & Development (United States), Janssen (Netherlands), Université de Lyon, Hospices Civils de Lyon, Seattle Cancer Care Alliance, University of Washington, Fred Hutch Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2902775612